BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fosigotifator readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fosigotifator\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04297683-7528@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Fosigotifator: Phase 2/3 readout est. (NCT04297683)
DESCRIPTION:Fosigotifator\, phase 2/3.\nStudy: HEALEY ALS Platform Trial - 
 Master Protocol\nEstimated primary completion: July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/fosigotifator#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04297683
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757141-7528@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fosigotifator: Phase 1/2 readout est. (NCT05757141)
DESCRIPTION:Fosigotifator\, phase 1/2.\nStudy: An Open-Label Exploratory St
 udy of Fosigotifator in Participants With Vanishing White Matter Disease\n
 Estimated primary completion: November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fosigotifator#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05757141
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272525-7528@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fosigotifator: Phase 1 readout est. (NCT07272525)
DESCRIPTION:Fosigotifator\, phase 1.\nStudy: Research Study for Single-Pati
 ent Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease\n
 Estimated primary completion: 30 November 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/fosigotifator#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07272525
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07300397-7528@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20290103
DTEND;VALUE=DATE:20290104
SUMMARY:Fosigotifator: Phase na readout est. (NCT07300397)
DESCRIPTION:Fosigotifator\, phase na.\nStudy: Single Patient Investigationa
 l Treatment for Cree Leukoencephalopathy\nEstimated primary completion: 3 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fosigot
 ifator#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07300397
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
